A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma
NCT ID: NCT01481077
Last Updated: 2013-09-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
77 participants
INTERVENTIONAL
2011-11-30
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment A
Latanoprost-PPDS
Sustained release for 12 weeks
Treatment B
Latanoprost-PPDS
Sustained release for 12 weeks
Treatment C
Latanoprost-PPDS
Sustained release for 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Latanoprost-PPDS
Sustained release for 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of bilateral open angle glaucoma or ocular hypertension
* Unmedicated IOP must be ≥22mm Hg
Exclusion Criteria
* No contact lens use for the length of the study
* Abnormal eye lids, eye infection or diseases to the eye
* Recent eye surgery
* Uncontrolled medical conditions
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mati Therapeutics Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Suzanne Cadden
Role: STUDY_DIRECTOR
QLT Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vold Vision
Springdale, Arkansas, United States
Glaucoma Consultants of Colorado, PC
Denver, Colorado, United States
Danbury Eye Physicians & Surgeons
Danbury, Connecticut, United States
Ophthalmology Consultants Inc.
Des Peres, Missouri, United States
Ophthalmology Associates
St Louis, Missouri, United States
Comprehensive Eye Care, Ltd
Washington, Missouri, United States
Las Vegas Physicians Research Group
Henderson, Nevada, United States
Abrams Eye Institute
Las Vegas, Nevada, United States
Philadelphia Eye Associates
Philadelphia, Pennsylvania, United States
University Eye Surgeons
Maryville, Tennessee, United States
Total Eye Care, P.A.
Memphis, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PPL GLAU 13
Identifier Type: -
Identifier Source: org_study_id